Materias dentro de su búsqueda.
Mostrando 926,201 - 926,220 Resultados de 928,171 Para Buscar '"8½"', tiempo de consulta: 5.56s Limitar resultados
  1. 926201
    “…At week 72, MMRM-estimated relative change in risk from baseline was -16.4%, -23.5%, -22.4%, and 12.7% for TZP 5/10/15mg and PBO, leading to significantly greater reduction for TZP groups compared to PBO (TZP 5 mg: -25.8%; 10 mg: -32.1%; 15 mg: -31.1%; p≤0.001). Among 272 participants (TZP 5 mg, n=83; 10 mg, n=66; 15 mg, n=55; PBO, n=68) with intermediate-to-high baseline ASCVD risk, median risk scores for TZP 5/10/15 mg and PBO groups were: baseline: 11.3%, 10.5%, 10.9%, 10.1%; week 72: 11.3%, 9.0%, 10.3%, 11.7%, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial
  2. 926202
    “…Teriparatide concentrations in serial blood samples (collected for up to 300 minutes) were quantitated via a validated ELISA.PD Study: OVX Sprague-Dawley rats (n=50) underwent an 8-week bone depletion period followed by 6-weeks of daily treatment with teriparatide at a dose of 2, 5, or 15 µg/kg via IP injection or 5 µg/kg via SC injection (Forteo®) (n = 10 per treatment). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SAT236 Pharmacokinetics (PK) And Pharmacodynamics (PD) Of The Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered Via An Orally Administered Robotic Pill (RT-102)
  3. 926203
    “…Nonclinical Proof-of-Concept: Single doses of RT-112 (150 IU (n=7) and 450 IU (n=8)) were orally administered to awake, fasted Beagle dogs (7.0-13.0 kg body weight); a control group (n=3) received a dose of 20 IU/kg (∼180 IU) FSH via SC injection. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)
  4. 926204
    “…BAT (18)F-FDG uptake (standard uptake value 5.1 ± 0.5 vs 4.2 ± 0.6 g/mL) and volume (69 ± 14 vs 72 ± 32 cm(3)) were similar between weight groups, despite greater insulin resistance in obese subjects (fasting glucose 5.5 ± 0.2 vs 4.3 ± 0.1mmol/L, insulin 11.9 ± 1.3 vs 5.8 ± 0.9mU/L, HOMA-IR 2.9 ± 0.3 vs 1.1 ± 0.2, free fatty acids 465 ± 78 vs 240 ± 34µM, all P<0.05), suggesting that (18)F-FDG uptake by BAT is not significantly affected by insulin resistance. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    OR07-03 UCP1 Expression In Human Brown Adipose Tissue Is Inversely Associated With Cardiometabolic Risk Factors
  5. 926205
    “…Among patients with lower initial TG values (<500: N=453,940; 500-999: N=8,847), TG testing patterns were largely comparable to those among SHTG patients. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI090 Patterns Of Triglyceride Testing And Results Over Time Among Patients With Diabetes And Severe Hypertriglyceridemia In US Clinical Practice
  6. 926206
    por Araujo-Castro, Marta, Paja Fano, Miguel, González Boillos, Marga, Pla Peris, Begoña, Pascual-Corrales, Eider, García Cano, Ana María, Parra, Paola, Martín Rojas-Marcos, Patricia, Ruiz-Sanchez, Jorge Gabriel, Vicente Delgado, Almudena, Gómez Hoyos, Emilia, Ferreira, Rui, García Sanz, Iñigo, Recasens Sala, Mònica, San Millan, Rebeca Barahona, Picón César, María José, Díaz Guardiola, Patricia, García González, Juan Jesús, Perdomo, Carolina M, Manjón Miguélez, Laura, García Centeno, Rogelio, Rebollo Román, Ángel, Gracia Gimeno, Paola, Robles Lázaro, Cristina, Morales-Ruiz, Manuel, Calatayud Gutiérrez, María, Andree Furio Collao, Simone Simone, Meneses, Diego, Sampedro Nuñez, Miguel Antonio, Escudero Quesada, Verónica, Mena Ribas, Elena, Sanmartin Sánchez, Alicia, Gonzalvo Diaz, Cesar, Lamas, Cristina, Hanzu, Felicia
    Publicado 2023
    “…We identified as risk factors of type 2 diabetes: male sex (OR 2.80 [1.81-4.34], P<0.001), older age (OR 1.05 [1.03-1.07], P<0.001), familiar history of T2DM (OR 4.64 [2.39-8.99]), P<0.001), dyslipidemia (OR 4.05 [2.67-6.14], P<0.001), cardiovascular (OR 1.30 [1.14-1.48], P<0.001) and cerebrovascular disease (OR 1.59 [0.92-2.74], P=0.003), sleep apnea syndrome (SAS) (OR 2.21 [1.34-3.63], P=0.003), higher BMI (OR 1.06 per unit [1.03-1.10], <0.001), hypertension duration (OR 1.04 per year [1.02-1.06], P<0.001) and the number of antihypertensive drugs (OR 1.50 [1.29-1.74], P<0.0001). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI145 Prevalence Of Type 2 Diabetes Mellitus And Risk Factors For Its Development In Patients With Primary Aldosteronism
  7. 926207
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes
  8. 926208
    “…Participants with 1 or 2 ARVs entered the RC and received open-label FTR + OBT after an 8-day blinded placebo-controlled period; those with 0 ARVs entered the NRC and received open-label FTR + OBT from Day 0. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
  9. 926209
    “…AZD3152 potently neutralizes authentic viral variants (EC(50) range, 8.3 to 110.9 ng/mL) and SARS-CoV-2 pseudoviruses (EC(50) range of 3.2 to 25.0 ng/mL), including XBB.1.5. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1355. The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals
  10. 926210
    “…One mRNA-1653 injection boosted hMPV and PIV3 nAb titers (GMFR over baseline: hMPV-A=2.9-6.1; hMPV-B=6.2-13.2; PIV3=2.8-3.0) and preF and postF bAb concentrations (GMFR: hMPV preF=5.3-6.1; postF=4.6-6.5 and PIV3 preF=13.9-14.2; postF=11.0-12.1); a second injection did not further increase antibody levels (Fig 1B,C and 2B,C). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2655. Phase 1 Safety and Immunogenicity Results of Two Investigational mRNA Vaccines, mRNA-1345, a Respiratory Syncytial Virus Vaccine, and mRNA-1653, a Human Metapneumovirus and Parainfluenza Virus Type 3 Combination Vaccine in Seropositive Young Children
  11. 926211
    “…SER-147 candidate strains were additionally assessed in vitro for their capacity to tolerate low pH, grow in hypoxic culture conditions, suppress IL-8 activity, and utilize lactulose as a sole carbon source as it is a commonly prescribed medication in the CLD patient population CONCLUSION: Patients with CLD are at increased risk of mortality from infections seeded from the GI tract due to microbiome disruption and GI barrier compromise. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2156. The Rational Design of SER-147: a Cultivated Microbial Consortium to Restore Colonization Resistance and Mitigate Infection in Chronic Liver Disease
  12. 926212
    “…Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020
  13. 926213
    “…CFDC (MIC(50/90), 0.25/1 mg/L; 95.7 %S) displayed better in vitro potency in CarbNS ABC as compared to SAM (MIC(50/90), 32/ >64 mg/L; 17.4 %S CLSI) and CST (MIC(50/90), 0.5/ >8 mg/L; 78.3%S EUCAST). Among pediatric S. maltophilia, CFDC was the most active agent with MIC(50/90,) 0.06/0.25 and 100 %S per CLSI & EUCAST breakpoints. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2790. Activity of Cefiderocol and Comparator Agents Against Pediatric Isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022)
  14. 926214
    “…Individual pathogens were introduced on day 4 of the experiment, followed by a vancomycin pre-treatment from days 5-8. On days 10-16, five unique candidate consortia (DE061, DE456, DE240, DE714, and DE492) were dosed daily as the microbiome intervention. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2067. Preclinical Characterization of Rationally Designed Microbial Consortia to Prevent Bacterial Infections in Patients with Chronic Liver Disease
  15. 926215
    “…HCoV-229E was the most common HCoV detected among inpatients (57.0%), followed by HCoV-HKU1-(45.2%); HCoV-OC43- (40.8%); and HCoV-NL63 (38.9%). Among those positive for a HCoV age, race, and insurance status were significantly associated with hospitalization. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1752. Seasonal Human Coronavirus in Pediatric Patients enrolled by the New Vaccine Surveillance Network, 2016-2020
  16. 926216
    “…Among tested antibiotic recipients, the predominant pathogens detected were norovirus [IP=58/422 (14%), ED=40/304 (13%)] and rotavirus [IP=89/886 (10%), ED=40/531 (8%)] without bacterial codetection, and Enteropathogenic E. coli [IP=10/93 (11%), ED=4/39 (10%)]. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    650. Antibiotic Use among Children Seeking Medical Care with Acute Gastroenteritis within the New Vaccine Surveillance Network, United States, 2011-2021
  17. 926217
    “…MicroRNA (miRNA) inhibitor and mimics, siRNA, PLKO-shRNA, and plenti6.3-miR-139 were used to upregulate or downregulate the expression of target genes. CCK8, EdU, clone formation, and senescence-associated β-galactosidase (SA-β-gal) staining assays were performed to assess cell proliferation and cellular senescence phenotypes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A
  18. 926218
    por Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Al-Shemari, Salem, Aurran-Schleinitz, Thérèse, Bacchiarri, Francesca, Bellido, Mar, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofia, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, Maria, Donaldson, David, Santos, Gimena Dos, Dreta, Barbara, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón-y-Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José-Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Kamel, Laribi, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, Maria, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, Lopez-Garcia, Alberto, Marquet, Juan, Martin-Rodríguez, Lucia, Maynadié, Marc, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Miras, Fatima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, Maria, Papajík, Tomas, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martin, Smirnova, Svetlana, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Tadmor, Tamar, Tomic, Kristina, Tse, Eric, Vassilakopoulos, Theodoros, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Panagiotidis, Panagiotis, Popov, Viola Maria, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine, Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Ghia, Paolo, Stamatopoulos, Kostas
    Publicado 2023
    “…CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
  19. 926219
    “…Eligible participants were boys and girls in the UK school years 8 and 9 (age 13–14 years). Participants completed a Time 1 (T1) survey (fertility knowledge, demographics) prior to watching the animations and a Time 2 (T2) survey (fertility knowledge, perceptions of the animations) immediately after the animations. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The effect of an educational animation on knowledge of testicular health and fertility of adolescents
  20. 926220
    “…Markers of vitamin insufficiency/deficiency were reduced in the intervention group, and the proportion of participants with vitamin D insufficiency (<50 nmol/L) during late pregnancy was lower in the intervention group (35.1% versus 8.5%; p < 0.0001). Plasma vitamin B12 remained higher in the intervention group than in the control group 6 months postdelivery (by 0.30 SDS (0.14, 0.46), p = 0.0003). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial
Herramientas de búsqueda: RSS